BioTime Acquires Asterias Biotherapeutics with Two of its Clinical Stage Cell Therapy Candidates

 BioTime Acquires Asterias Biotherapeutics with Two of its Clinical Stage Cell Therapy Candidates

BioTime Acquires Asterias Biotherapeutics with Two of its Clinical Stage Cell Therapy Candidates

Shots:

  • Asterias to receive 0.71 share, for each of its share in BioTime making it an ownership of 16.2%. Biotime to get hold of all stock of Asterias along with two clinical stage candidates i.e. OPC1 & VAC2
  • The focus of the acquisition is to develop & commercialize novel therapies in fields of Immuno-oncology & Neurology
  • OPC1 is a therapy utilizing oligodendrocyte progenitor cells (OPCs), is currently evaluated in P-II for the treatment of Severe Spinal Cord Injury. VAC2 is an immunotherapy candidate, currently evaluated in P-I for the treatment of NSCLC in collaboration with Cancer Research UK

Click here to read full press release/ article | Ref: BioTime | Image: Commons Wikimedia

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post